Latest news
What Oblenio’s Phase I trial means for autoimmune drug discovery - Drug Target ReviewDrug Target Review · Wed, 05 Aug 2026 14:00:01 GMTJ&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy - MedCity NewsMedCity News · Thu, 30 Jul 2026 07:00:00 GMTJohnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset - Business WireBusiness Wire · Wed, 29 Jul 2026 07:00:00 GMT